Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer

BACKGROUND: Increasing evidence supporting the role of immune checkpoint blockade in cancer management has been bolstered by recent reports demonstrating significant and durable clinical responses across multiple tumour types, including metastatic urothelial carcinoma (mUC). The majority of these re...

Descripción completa

Detalles Bibliográficos
Autores principales: Bidnur, S., Savdie, R., Black, P.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927995/
https://www.ncbi.nlm.nih.gov/pubmed/27376121
http://dx.doi.org/10.3233/BLC-150026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927995/
https://www.ncbi.nlm.nih.gov/pubmed/27376121
http://dx.doi.org/10.3233/BLC-150026

Ejemplares similares